Compass Pathways plc is a pioneering mental health care company focused on developing innovative psychedelic therapies, notably leveraging psilocybin, to address significant unmet needs in the treatment of mental health conditions. Headquartered in Cheshire, UK, the firm is engaged in rigorous clinical research in both the UK and US, primarily targeting treatment-resistant depression. Through its dedication to advancing research and fostering transformative therapies, Compass Pathways aims to redefine mental health care standards and improve patient outcomes worldwide, positioning itself as a leader in the emerging field of psychedelic-assisted therapy. Show more
Location: 33 BROADWICK STREET, LONDON, UNITED KINGDOM, W1F 0DQ, London, W1F 0DQ, USA | Website: https://compasspathways.com | Industry: MEDICAL CARE FACILITIES | Sector: HEALTHCARE
Market Cap
642.4M
52 Wk Range
$2.25 - $8.20
Previous Close
$6.79
Open
$6.77
Volume
1,015,654
Day Range
$6.49 - $6.85
Enterprise Value
491.6M
Cash
185.9M
Avg Qtr Burn
-35.11M
Insider Ownership
12.12%
Institutional Own.
62.06%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
COMP360 (Psilocybin) Details Treatment Resistant Depression | Phase 3 Data readout | |
COMP360 (Psilocybin) Details Post-traumatic stress disorder | Phase 2/3 Initiation | |
COMP360 (Psilocybin) Details Anorexia nervosa | Phase 2 Update |
